https://www.selleckchem.com/pr....oducts/BAY-73-4506.h
Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (CNV) profiling and targeted panel sequencing from cell-free DNA (cfDNA) to monitor ALK NSCLC. 271 longitudinal plasma DNA samples from 73 patients with TKI-treated metastatic ALK NSCLC were analysed by capture-based targeted (average coverage 4,100x), a
إعجاب
علق
شارك
